VivoSeq
Oncology

Sarcoma

7

Pipeline Programs

14

Active Trials

7

Companies Involved

Sarcoma is an early-stage landscape with 7 programs across 7 companies. The most active players are Amgen, Avyxa, Eastern Cooperative Oncology Group. 5 programs are in Phase 3.

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

22/100

Mech. Concentration

40/100

Completion Rate

73/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

8programs
Small molecule338%
Protein / enzyme225%
Monoclonal antibody113%
Cell therapy113%
Vaccine113%

Modality classified for 89% of 9 pipeline programs.

Trial Status

30

clinical trials

Completed11 · 37%
Active, not recruiting6 · 20%
Recruiting6 · 20%
Terminated3 · 10%
Not yet recruiting2 · 7%
Unknown status1 · 3%
Other1 · 3%

Trial Activity

30 trials

FAZA PET/MRI Sarcoma
Active, not recruiting·UUniversity Health Network, Toronto·N/A·NCT03418818·70 enrolled
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
Active, not recruiting··Phase 1/2·NCT04599062·8 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)